Pay in 4 interest-free payments of $7.33 Learn more
Ships within 48 hours · Estimated delivery Aug 10 - Aug 15
10.1016/j.molmet.2017.05.002 107 ShinN.-R.LeeJ.-C.LeeH.-Y.KimM.-S.WhonT
At 12 mg: 28.7% average weight loss Significant improvement in WOMAC pain scores more than 1 in 8 patients became completely free of knee pain Dysesthesia (tingling, altered skin sensation) in 20.9% of patients at 12 mg vs
Immunology 172, 451468
Chronic weight management
Host-microbial cross-talk in inflammatory bowel disease
Sitagliptin, a dipeptidyl peptidase-4 inhibitor, was selected as an active-comparator placebo proxy because it was recommended in clinical guidelines as a second-line glucose-lowering therapy, had a similar high cost to the study drugs, showed no effect on cardiovascular outcomes in a large randomized controlled trial and has been validated as a placebo proxy in prior claims-based research 20,41
US$ 21.30
US$ 26.55
US$ 25.79
US$ 25.38
